Avalon GloboCare Partners with Weill Cornell Medical College for CAR-T Production Technologies

Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.
Aug 08, 2018
By Pharmaceutical Technology Editors
Volume 13, Issue 9

On Aug. 7, 2018, Avalon GloboCare, a developer of cell-based technologies and therapeutics, announced that it has formed a strategic partnership with Weill Cornell Medical College’s cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering, headed by Dr. Yen-Michael Hsu, to co-develop bio-production and standardization procedures for the procurement, storage, processing, clinical study protocols, and bio-banking of chimeric antigen receptor (CAR)-T therapy. The bio-production and standardization procedures will comply with Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards.

The partnership will enable Avalon GloboCare to implement laboratory infrastructure and clinical plans developed in China and the United States resulting from the collaboration. The partnership also includes a CAR-T education program to support and foster collaborative research and training programs for scientists and clinicians between Weill Cornell and China’s Hebei Yanda LuDaopei Hospital, Avalon GloboCare’s main affiliated clinical facility and a major global medical institution in CAR-T therapy.

"This strategic partnership will synergize Weill Cornell’s world-class cGMP cellular therapy facility and our immense clinical resources at the LuDaopei hospital network to accelerate innovative CAR-T technology development, standardization in bio-manufacturing process, as well as knowledge exchange in CAR-T and other cellular therapies. Last month, we announced that Avalon formed a new wholly owned US subsidiary, Avactis Biosciences, Inc., which will be focused on accelerating commercial activities related to our proprietary CAR-T technologies.  This new subsidiary is designed to integrate and optimize our global scientific and clinical resources, which will be instrumental as we advance this partnership with Weill Cornell," stated Dr. David Jin, CEO and president of Avalon GloboCare and the recently established CAR-T-focused subsidiary Avactis Biosciences, in a company press release. "We are very proud to initiate this endeavor with an overarching goal of integrating premium research and clinical resources worldwide to provide standardized, safer, and more effective CAR-T therapy." added Dr. Jin.

Source: Avalon GloboCare

native1_300x100
lorem ipsum